Nhlbi
Nhlbi funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
PAR-24-211: NHLBI Career Transition Award (K22 Clinical Trial Required)
NHLBI K22 career transition award for doctoral-level researchers in the NHLBI Division of Intramural Research who are preparing to lead an independent clinical trial, feasibility study, or ancillary clinical trial at an extramural institution.
PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (U24)
The NHLBI PAR-27-013 funding opportunity supports Data Coordinating Center (DCC) teams that coordinate multi-site investigator-initiated clinical trials in a milestone-driven cooperative agreement, submitted alongside a companion Clinical Coordinating Center application. The next listed application due date is October 2, 2026.
RFA-HL-26-002: NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
The NHLBI Outstanding Investigator Award provides up to 7 years of flexible R35 support, with applications requesting up to $700,000 in direct costs per year, for established investigators whose programs advance heart, lung, blood, and sleep research.
RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)
NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.
RFA-HL-26-016: Catalyze Enabling Technologies and Transformative Platforms for HLBS Research (R33)
The National Heart, Lung, and Blood Institute's Catalyze R33 supports further development and rigorous validation of transformative, multi-use technologies and platforms relevant to heart, lung, blood, and sleep research. The next listed application due date is 2026-10-21.
RFA-HL-26-018: Catalyze Product Definition for Small Molecules, Biologics, and Combination Products
An NIH R33 Catalyze Product Definition NOFO for early translational work that identifies a lead compound series and tests a combination-product prototype for heart, lung, blood, and sleep diseases. The next announced application date is October 21, 2026.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33; Clinical Trial Not Allowed)
NIH NHLBI Catalyze Product Definition NOFO for early-stage device, diagnostic, and research-tool development in heart, lung, blood, and sleep diseases. The next new-application due date is October 21, 2026.
RFA-HL-27-004: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
NIH’s NHLBI RFA-HL-27-004 is a limited-competition R03 small grant opportunity to help current and recently completed NHLBI K01/K08/K23/K25 awardees advance toward independent funding through a short, NIH-funded pilot- to proof-of-concept scale project.